Based on this evidence, the independent appraisal committee is unable to recommend golimumab for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate. The draft recommendation is available for consultation; NICE has not yet issued final guidance to the NHS.
A NICE spokesperson said: “The independent advisory committee reviewed the evidence on golimumab, including evidence on the nature of psoriatic arthritis, the views of people with the condition, those who represent them, and clinical specialists.
The Committee understood that psoriatic arthritis can cause significant distress and psychological impact on an individual’s life, employment and social activities.
“NICE currently recommends adalimumab, etanercept and infliximab for the treatment of psoriatic arthritis in people who have peripheral arthritis in technology appraisal guidance199. The cost-effectiveness analyses found that golimumab was not the most cost effective of the available options currently recommended by NICE.
As the long term follow-up on adverse event outcomes is yet to be completed, the Committee considered there to be uncertainty about the long-term adverse event profile of golimumab.
Whilst recognising the severity of the disease, the Committee concluded that based on the available evidence, golimumab was expected to be more costly than estimated in the economic model and less cost effective than etanercept, and so could not be considered a good use of NHS resources. We welcome comments on this draft recommendation as part of the consultation.”
Source: NICE